Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31336880 | 0.90 | PDE2A (0.39) | PDE2ACSNK1DMAPK14KDM4CSLC34A1 | |
| SCHEMBL31336633 | 0.83 | KDM4C (0.30) | KDM4C | |
| SCHEMBL31336654 | 0.77 | GRM5 (0.38) | CSNK1DMAPK14GRM5NPC1RXFP1 | |
| SCHEMBL28927799 | 0.73 | HCRTR1 (0.33) | PDE2AKDM4C | |
| SCHEMBL31336717 | 0.72 | GABRA5 (0.38) | GRM5 | |
| SCHEMBL31336831 | 0.71 | CCR1 (0.33) | PDE2AKDM4CNPC1 | |
| SCHEMBL31336809 | 0.71 | POLB (0.40) | PDE2ANPC1RXFP1 | |
| SCHEMBL31336916 | 0.69 | — | — | |
| SCHEMBL31336898 | 0.68 | CSNK1D (0.44) | CSNK1DMAPK14 | |
| SCHEMBL31336683 | 0.67 | GRM5 (0.43) | CSNK1DMAPK14GRM5NPC1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025023851-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |